▲ +67.27% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for SWK in the last 3 months. The average price target is $23.00, with a high forecast of $23.00 and a low forecast of $23.00. The average price target represents a 67.27% upside from the last price of $13.75.
The current consensus among 2 polled investment analysts is to buy stock in SWK.
SWK Holdings Corporation, a specialized finance company, focuses on the healthcare sector. The company operates through two segments, Finance Receivables and Pharmaceutical Development. It provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. The company, through its subsidiary, SWK Advisors LLC, offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. The company also engages in the pharmaceutical development, formulation and manufacturing, and licensing business through the Peptelligence platform. Its product pipeline includes Ovarest, an oral leuprolide tablet to treat endometriosis; and Tobrate, an oral tobramycin tablet for the treatment of uncomplicated urinary tract infections. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was founded in 1996 and is headquartered in Dallas, Texas.